natgillin/translations-raw huggingface dataset:
In the absence of carcinogenicity study data, and due to lack of clinical experience with repeated courses of treatment in humans, no more than two courses of Eurartesim should be given in a 12-month period (see sections 4.2 and 5.3). 
Zaradi pomanjkanja podatkov študij kancerogenosti in zaradi pomanjkanja kliničnih izkušenj s ponavljanjem ciklov zdravljenja pri ljudeh ni mogoče priporočiti več kot dva cikla zdravljenja z zdravilom Eurartesim v 12-mesečnem obdobju (glejte poglavji 4.2 in 5.3).
Reactions such as cough, pyrexia, headache, P. falciparum infection, anaemia, asthenia, anorexia and the observed changes in blood cell parameters are consistent with those expected in patients with acute malaria. 
Reakcije, kot so kašelj, pireksija, glavobol, okužba s P. falciparum, anemija, astenija, anoreksija in opažene spremembe parametrov krvnih celic so bile konsistentne s pričakovanimi za bolnike z akutno malarijo.
Side effects in adults 
Neželeni učinki pri odraslih
30.400 00071 Pomezia (Rome) Italy 
30,400 00071 Pomezia (Rim) Italija
Taking this medicine, if the malaria infection returns 
Jemanje zdravila pri ponovitvi okužbe z malarijo
Via Pontina Km 30.400 IT-00071 Pomezia (RM) Italy 
Via Pontina Km 30.400 IT-00071 Pomezia (RM) Italija
Reproductive studies with artemisinin derivatives have demonstrated teratogenic potential with an increased risk during early gestation (see section 5.3). 
Študije vpliva na razmnoževanje z derivati artemizinina so pokazale teratogeni potencial z zvečanim tveganjem v zgodnji nosečnosti (glejte poglavje 5.3).
Piperaquine has the potential to increase the rate of metabolism for CYP2E1 substrates resulting in a decrease in the plasma concentrations of substrates such as paracetamol or theophylline, and the anaesthetic gases enflurane, halothane and isoflurane. 
Piperakin ima potencial za zviševanje stopnje presnove za substrate encima CYP2E1, kar povzroči zmanjšanje koncentracij v plazmi za substrate kot so paracetamol ali teofilin in plini za anestezijo enfluran, halotan in izofluran.
Women taking Eurartesim should not breast-feed during their treatment. 
Ženske, ki jemljejo zdravilo Eurartesim, naj med zdravljenjem ne dojijo.
Considering the possibility of age-associated decrease in hepatic and renal function, as well as a potential for heart disorders (see sections 4.3 and 4.4), caution should be exercised when administering the product to the elderly. 
Ob upoštevanju možnosti s starostjo povezanega zmanjšanja delovanja jeter in ledvic ter možnosti za bolezni srca (glejte poglavji 4.3 in 4.4) je potrebna pri dajanju tega zdravila starejšim bolnikom previdnost.
diazepam, alprazolam), zaleplon, zolpidem; 
alprazolam, zaleplon, zolpidem),
ANNEX II A MANUFACTURER RESPONSIBLE FOR BATCH RELEASE B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT 
A. IZDELOVALEC, ODGOVOREN ZA SPROŠČANJE SERIJ B. POGOJI ALI OMEJITVE GLEDE OSKRBE IN UPORABE C. DRUGI POGOJI IN ZAHTEVE DOVOLJENJA ZA
Eurartesim has not been evaluated in patients with moderate or severe renal or hepatic insufficiency (see section 4.2). 
Zdravilo Eurartesim ni bilo ovrednoteno pri bolnikih z zmerno ali hudo ledvično ali jetrno insuficienco (glejte poglavje 4.2).
Analysis of cardiac adverse events in clinical trials showed that these were reported more frequently in Eurartesim treated patients than in those treated with comparator antimalarial (see section 4.8). 
Analiza srčnih neželenih učinkov v teh kliničnih preskušanjih je pokazala, da so bili poročani pogosteje pri bolnikih, zdravljenih z zdravilom Eurartesim, kot pri bolnikih, zdravljenih s primerljivimi antimalariki (glejte poglavje 4.8).
If you or your child vomit also the second dose, do not take or give your child another dose. 
Če vi ali vaš otrok izbruhate tudi drugi odmerek, ne vzemite še enega ali otroku ne dajte še enega.
What Eurartesim is and what it is used for What you need to know before you or your child takes Eurartesim How to take Eurartesim 
Kaj je zdravilo Eurartesim in za kaj ga uporabljamo Kaj morate vedeti, preden boste vi ali vaš otrok vzeli zdravilo Eurartesim Kako jemati zdravilo Eurartesim
Animal data suggest excretion of piperaquine into breast milk but no data are available in humans. 
Podatki na živalih kažejo, da se piperakin izloča v mleko, vendar za ljudi ni na voljo podatkov.
These patients should not receive another dose of Eurartesim and alternative antimalarial therapy should be instituted. 
Ti bolniki ne smejo prejeti še drugega odmerka zdravila Eurartesim, temveč se naj začnejo zdraviti z alternativnim antimalarikom.
Animal studies showed that radiolabelled piperaquine is excreted by the biliary route, while urinary excretion is negligible. 
Študije na živalih so pokazale, da se radioaktivno označen piperakin izloča prek žolča, medtem ko je izločanje v urinu zanemarljivo.
Artenimol and piperaquine were not genotoxic/clastogenic based on in vitro and in vivo testing. 
Artenimol in piperakin nista bila genotoksična/klastogena v preskušanjih in vitro in in vivo.
The ADRs noted for Eurartesim were generally mild in severity, and the majority were non-serious. 
Neželeni učinki, ki so jih opazili pri jemanju zdravila Eurartesim, so bili na splošno blagi in večinoma niso bili resni.
The association of artenimol and piperaquine does not produce hERG inhibition greater than that of the single compounds. 
Povezava artenimola in piperakina ne povzroči večjega zaviranja hERG kot pri eni sami sestavini.
In the European Safety Registry 25 patients weighing ≥ 100 kg (range 100 -121 kg) were treated with 4 tablets 320/40 mg PQP/artenimol for 3 days. 
V evropski študiji varnosti so 25 bolnikov s telesno maso ≥ 100 kg (razpon od 100 kg do 121 kg) 3 dni zdravili s 4 tabletami 320 mg/40 mg PKP/artenimola.
The age-specific PCR-corrected cure rates in the m-ITT populations are tabulated below for the Asian and African studies, respectively: 
Za starost specifične stopnje ozdravljenja, popravljene za PCR, v populacijah m-ITT za študiji v Aziji in Afriki, so predstavljene v spodnji tabeli:
Artenimol administration may result in a slight decrease in CYP1A2 activity. 
Dajanje artenimola lahko povzroči rahlo zmanjšanje aktivnosti encima CYP1A2.
The bulky bisquinolone structure may be important for activity against chloroquine- resistant strains, and may act through the following mechanisms: 
Obsežna zgradba biskinolona je morda pomembna pri aktivnosti proti sevom, odpornim na klorokin, in lahko deluje preko naslednjih mehanizmov:
Piperaquine is a bisquinoline, and this class has shown good antimalarial activity against chloroquineresistant Plasmodium strains in vitro. 
Piperakin je biskinolon in ta razred kaže in vitro dobro antimalarično aktivnost proti sevom plazmodija, odpornim na klorokin.
Resistance to piperaquine (when used as monotherapy) has been reported. 
Poročali so o odpornosti na piperakin (če se uporablja kot monoterapija).
In a second randomised trial, 1,038 children, aged between 6 months and 5 years, were exposed to Eurartesim and 71% were judged to have experienced an ADR. 
V drugem randomiziranem preskušanju je bilo zdravilu Eurartesim izpostavljenih 1.038 otrok, starih med 6 meseci in 5 let, in ocenjeno je bilo, da je imelo 71 % preiskovancev neželene učinke.
Other medicines and Eurartesim 
Druga zdravila in zdravilo Eurartesim
The number of subjects with QTcF greater than 480 msec after dosing with low fat meals was 3/64, while 10/64 had QTcF values over this threshold after dosing with high fat meals. 
Število oseb s QTcF, višjim od 480 msek, po odmerjanju z obroki z nizko vsebnostjo maščob je bil 3/64, medtem ko jih je imelo 10/64 vrednosti QTcF nad tem pragom po odmerjanju z obroki z visoko vsebnostjo maščob/kalorij.
The QTcF prolongation observed under fasting conditions lasted between 4 and 11 hours after the last dose was administered on Day 3. 
Podaljšanje QTcF, ki so ga opazili na tešče, je trajalo med 4 in 11 ur po dajanju zadnjega odmerka 3. dne.
Sometimes a problem with your red blood cells, called haemolytic anaemia can occur after receiving malaria treatment. 
Včasih se lahko po zdravljenju malarije pojavi težava z vašimi rdečimi krvnimi celicami, imenovana hemolitična anemija.
Compared to placebo, the maximum mean increases in QTcF on Day 3 of dosing with Eurartesim were 45.2, 35.5 and 21.0 msec under respective dosing conditions. 
V primerjavi s placebom so bila največja povprečna podaljšanja v QTcF 3. dan po dajanju zdravila Eurartesim 45,2, 35,5 in 21,0 msek pod opisanimi pogoji odmerjanja.
Food interaction 
Medsebojno delovanje s hrano
- History of symptomatic cardiac arrhythmias or with clinically relevant bradycardia. 
- Anamneza simptomatskih srčnih aritmij, klinično pomembne bradikardije.
− macrolides (e.g. erythromycin, clarithromycin), 
− makrolidi (npr. eritromicin, klaritromicin),
If the second dose is vomited, alternative antimalarial therapy should be instituted. 
Če bolnik drugi odmerek izbruha, je treba uvesti zdravljenje z alternativnim antimalarikom.
Eurartesim tablets are packaged in PVC/PVDC/aluminium blisters containing 3, 6, 9 or 12 tablets. 
Tablete zdravila Eurartesim so pakirane v pretisne omote iz PVC/PVDC/aluminija, ki vsebujejo 3, 6, 9 ali 12 tablet.
- Any predisposing cardiac conditions for arrhythmia such as severe hypertension, left ventricular hypertrophy (including hypertrophic cardiomyopathy) or congestive cardiac failure accompanied by reduced left ventricle ejection fraction. 
- Kakršna koli bolezen srca, ki povečuje dovzetnost za razvoj aritmij, kot je huda hipertenzija, hipertrofija levega prekata (vključno s hipertrofično kardiomiopatijo) ali kongestivno srčno popuščanje, ki ga spremlja zmanjšan iztisni delež levega prekata.
EU/1/11/716/001 3 film-coated tablets EU/1/11/716/002 6 film-coated tablets EU/1/11/716/003 9 film-coated tablets EU/1/11/716/004 12 film-coated tablets 
EU/1/11/716/001 3 filmsko obložene tablete EU/1/11/716/002 6 filmsko obloženih tablet EU/1/11/716/003 9 filmsko obloženih tablet EU/1/11/716/004 12 filmsko obloženih tablet
If you are taking folate supplements to prevent possible neural tube birth defects, you can continue taking them at the same time as Eurartesim. 
Če jemljete folate kot dopolnilno zdravljenje za preprečevanje morebitnih okvar nevralne cevi, lahko s tem nadaljujete med jemanjem zdravila Eurartesim.
If you notice anything different about your or your child's heart rhythm or have symptoms (such as palpitations or irregular heart beat) you should contact your doctor as soon as possible and before the next dose is due. 
Če opazite kakršno koli spremembo v svojem ali otrokovem srčnem ritmu ali če imate vi ali vaš otrok simptome (kot so palpitacije ali nepravilen srčni utrip), se obrnite na zdravnika takoj, ko je to mogoče in še preden morate vi ali vaš otrok vzeti naslednji odmerek.
If this happens, talk to your doctor. 
V tem primeru se pogovorite z zdravnikom.
The primary end-point was PCR-corrected cure rate at Day 28. 
Primarni končni opazovani dogodek je bila stopnja ozdravljenja, popravljena za PCR, na 28. dan.
In the hERG test, the IC50 was 0.15 µmol for piperaquine and 7.7 µmol forartenimol. 
V testu hERG je bil IC50 0,15 µmol za piperakin in 7,7 µmol za artenimol.
Artenimol causes embryolethality and teratogenicity in rats and rabbits. 
Artenimol povzroča smrtnost zarodkov in teratogenost pri podganah in kuncih.
Delayed Haemolytic Anaemia 
Zakasnjena hemolitična anemija
Due to the potential for higher plasma concentrations of piperaquine to occur, caution is advised if Eurartesim is administered to patients with jaundice and/or with moderate or severe renal or hepatic insufficiency, and ECG and blood potassium monitoring are advised. 
Zaradi možnosti višjih koncentracij piperakina v plazmi je potrebna previdnost pri dajanju zdravila Eurartesim bolnikom z zlatenico in/ali zmerno ali hudo ledvično ali jetrno insuficienco, priporoča pa se tudi spremljanje EKG in kalija v krvi.
• That patients should be advised to contact their doctor about adverse events and that physicians/pharmacists should report suspected adverse reactions to Eurartesim, and in particular, those associated with a QT prolongation. 
• Bolnike je treba opozoriti, da se o neželenih učinkih posvetujejo z zdravnikom, in da mora zdravnik/farmacevt poročati domnevne neželene učinke z zdravilom Eurartesim, še zlasti tiste, ki so povezani s podaljšanjem intervala QT.
Accordingly, Eurartesim should be administered with water no less than 3 hours after the last food intake, and no food should be taken within 3 hours after each dose (see section 4.2). 
Ustrezno je treba zdravilo Eurartesim dajati z vodo vsaj 3 ure po zadnjem vnosu hrane, nato pa se hrane ne sme uživati 3 ure po vsakem obroku (glejte poglavje 4.2).
Central nervous system (CNS) toxicity 
Toksičnost za osrednji živčni sistem (OŽS)
Artenimol is principally converted to α-artenimol-β-glucuronide (α-artenimol-G). 
Artenimol se v glavnem pretvori v α-artenimol-β-glukuronid (α-artenimol-G).
SPECIAL STORAGE CONDITIONS Do not store above 30°C 
POSEBNA NAVODILA ZA SHRANJEVANJE Shranjujte pri temperaturi do 30 °C.
Within each frequency grouping, adverse reactions are presented in the order of decreasing seriousness, using the following convention: Very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), not known 
Znotraj vsake pogostnostne skupine so neželeni učinki navedeni po padajoči resnosti v skladu z naslednjim dogovorom: zelo pogosti (≥1/10), pogosti (≥1/100 do <1/10), občasni (≥1/1.000 do <1/100), redki (≥1/10.000 do <1/1.000), zelo redki (<1/10.000), neznana pogostnost (ni mogoče oceniti iz razpoložljivih podatkov).
Eurartesim tablets are packaged in PVC/PVDC/aluminium blisters containing 3 tablets. 
Tablete zdravila Eurartesim so pakirane v pretisne omote iz PVC/PVDC/aluminija, ki vsebujejo 3 tablete.
• That Eurartesim has a potential to prolong the QTc interval that may lead to potentially lethal arrhythmias. 
• Zdravilo Eurartesim lahko podaljša interval QTc, kar lahko povzroči aritmije, ki so lahko smrtne.
Eurartesim treatment was compared with Artesunate + Mefloquine (AS + MQ). 
Zdravljenje z zdravilom Eurartesim so primerjali z zdravljenjem s kombinacijo artesunat + meflokin (AS + MQ).
• Inhibition of the transporters that efflux chloroquine from the parasite food vacuole 
• zaviranje transporterjev, ki izlivajo klorokine iz vakuole hrane parazita,
• That piperaquine absorption is increased in the presence of food, therefore to reduce this risk of QTc interval prolongation, the patients should be advised to take the tablets with water, without food, no less than three hours after the last food intake. 
• Absorpcija piperakina se poveča v prisotnosti hrane, zato je treba bolnikom svetovati, da zdravilo vzamejo z vodo in brez hrane vsaj tri ure po zadnjem zaužitju hrane, da tako zmanjšajo tveganje podaljšanja intervala QTc.
Clinical studies of Eurartesim did not include patients aged 65 years and over, therefore no dosing recommendation can be made. 
Bolniki, stari 65 let in več, niso bili vključeni v klinične študije z zdravilom Eurartesim, zato priporočil za odmerjanje ni mogoče dati.
The mean oral clearance for adult patients with malaria was 1.34 l/h/kg. 
Povprečni peroralni očistek za odrasle bolnike z malarijo je bil 1,34 l/h/kg.
Caution is recommended when co-administering Eurartesim with medicinal products exhibiting variable patterns of inhibition, induction or competition for CYP3A4 as the therapeutic and/or toxic effects of some co-administered medicinal products could be altered. 
Previdnost je potrebna pri kombiniranju zdravila Eurartesim z zdravili, ki kažejo različne vzorce zaviranja, induciranja ali tekmovanja za encim CYP3A4, saj se lahko s tem spremenijo terapevtski in/ali toksični učinki nekaterih sočasno uporabljenih zdravil.
artenimol systemic exposure on the last day of treatment was higher in females than in males, the difference being within 30%. 
Sistemska izpostavljenost artenimolu zadnji dan zdravljenja je bila višja pri ženskah kot pri moških, pri čemer je bila razlika 30 %.
Moreover, data obtained in animal studies show that fertility is unaffected by artenimol in both females and males. 
Podatki, zbrani iz študij na živalih, kažejo, da artenimol ne vpliva na plodnost niti pri ženskah niti pri moških.
You or your child should take each dose no less than 3 hours after the last food intake, and no food should be taken within 3 hours after each dose of Eurartesim. 
Vsak odmerek vzemite (vi ali vaš otrok) vsaj 3 ure po zadnjem vnosu hrane, nato pa hrane ne smete uživati 3 ure po vsakem odmerku zdravila Eurartesim.
The mean oral clearance for adult patients with malaria was 2.09 l/h/kg, while in paediatric patients was 2.43 l/h/kg. 
Povprečni peroralni očistek za odrasle bolnike z malarijo je bil 2,09 l/h/kg, medtem ko je bil za pediatrične bolnike 2,43 l/h/kg.
This leaflet was last revised in month YYYY 
Navodilo je bilo nazadnje revidirano dne meseca LLLL
Therefore, ECG monitoring during the following 24-48 hours should be applied for patients found to have a prolongation to this extent. 
Zato je treba pri bolnikih, pri katerih so ugotovili podaljšanje v taki meri, uvesti nadziranje z EKG v obdobju naslednjih 24-48 ur.
• If you or your child gets another attack of malaria, you may take a second course of Eurartesim within one year if your doctor thinks this is a suitable treatment. 
• Če vi ali vaš otrok dobite ponovni napad malarije, lahko jemljete ponoven cikel zdravila Eurartesim v roku enega leta, če zdravnik meni, da je to ustrezno zdravljenje.
In healthy volunteers, piperaquine exposure is increased approximately 3-fold when administered with a high fat/high calorie meal. 
Pri zdravih prostovoljcih se izpostavljenost piperakinu poveča približno za 3-krat, če se daje z obrokom z visoko vsebnostjo maščob/visokokaloričnim obrokom.
Take at least 3 hours before or after food. 
DRUGA POSEBNA OPOZORILA, ČE SO POTREBNA Vzemite vsaj 3 ure pred obrokom hrane ali po njem.
- Recent treatment with medicinal products known to prolong the QTc interval that may still be circulating at the time that Eurartesim is commenced (e.g. mefloquine, halofantrine, lumefantrine, chloroquine, quinine and other antimalarial medicinal products) taking into account their elimination half-life. 
- Nedavno zdravljenje z zdravili, za katera je znano, da podaljšujejo interval QTc, ki lahko še vedno cirkulirajo v času uvedbe zdravila Eurartesim (npr. meflokin, halofantrin, lumefantrin, klorokinin, kinin in drugi antimalariki), ob upoštevanju njihovega razpolovnega časa izločanja.
The primary end-point was the PCR-corrected cure rate at Day 63. 
Primarni končni opazovani dogodek je bila stopnja ozdravljenja, popravljena za PCR, na 63. dan.
− fluoroquinolones (e.g. moxifloxacin, sparfloxacin), 
− fluorokinoloni (npr. moksifloksacin, sparfloksacin),
These medicines include: mefloquine, halofantrine, lumefantrine, chloroquine or quinine 
Ta zdravila vključujejo: meflokin, halofantrin, lumefantrin, klorokin ali kinin.
Piperaquine did not induce malformation in rats and rabbits. 
Piperakin ni induciral malformacij pri podganah in kuncih.
• That Eurartesim is contraindicated in patients with severe malaria according to WHO definition and in patients with a history of clinical conditions that may lead to QTc interval prolongation, and in patients taking drugs that are known to prolong the QTc interval. 
• Zdravilo Eurartesim je kontraindicirano pri bolnikih s hudo obliko malarije po opredelitvi SZO in pri bolnikih z anamnezo kroničnih stanj, ki lahko povzročijo podaljšanje intervala QTc, ter pri bolnikih, ki jemljejo zdravila, za katera je znano, da podaljšajo interval QTc.
This increase in exposure to the antimalarial combination may result in an exacerbation of the effect on QTc (see section 4.4). 
To zvečanje izpostavljenosti protimalarični kombinaciji zdravil lahko poslabša učinek na interval QTc (glejte poglavje 4.4).
Eurartesim treatment was compared with Artemether + Lumefantrine (A + L). 
Zdravljenje z zdravilom Eurartesim so primerjali z zdravljenjem s kombinacijo artemeter + lumefantrin (A + L).
Patients and caregivers should be advised to be vigilant for signs and symptoms of post-treatment haemolysis such as pallor, jaundice, dark-coloured urine, fever, fatigue, shortness of breath, dizziness and confusion. 
Bolnikom in negovalcem je treba naročiti, da morajo biti pozorni na znake in simptome hemolize po zdravljenju, kot so bledica, zlatenica, temen urin, zvišana telesna temperatura, utrujenost, kratka sapa, omotičnost in zmedenost.
- Known congenital prolongation of the QTc-interval or any clinical condition known to prolong the QTc interval. 
- Znano prirojeno podaljšanje intervala QTc ali katero koli klinično stanje, za katerega je znano, da podaljšuje interval QTc.
The 160 mg/20 mg tablets have the letters ‘S' and ‘T' on one side and come in blisters containing 3 tablets. 
Tablete 160 mg/20 mg imajo na eni strani črki „S“ in „T“ in so na voljo v pretisnih omotih s 3 tabletami.
Due to its long elimination half-life, piperaquine accumulates after multiple dosing. 
Zaradi svoje dolge razpolovne dobe izločanja se piperakin po večkratnem odmerjanju kopiči.
tacrolimus); - sex hormones, including those contained in hormonal contraceptives (such as gestodene, 
takrolimus), - spolni hormoni, vključno s tistimi v hormonskih kontraceptivih (kot so gestoden, progesteron,
Artenimolwas observed to have a small volume of distribution in humans (0.8 l/kg; CV 35.5%). 
Opazili so, da ima artenimol majhen volumen porazdelitve pri ljudeh (0,8 l/kg; CV 35,5 %).
The mean clearance (1.45 l/h/kg) was slightly faster in the paediatric patients than in the adult patients (1.34 l/h/kg), while the mean volume of distribution in the paediatric patients (0.705 l/kg) was lower than in the adults (0.801 l/kg). 
Povprečni očistek (1,45 l/h/kg) je bil nekoliko večji očistek za pediatrično populacijo kot za odrasle bolnike (1,34 l/h/kg), medtem ko je bil povprečni volumen porazdelitve za pediatrične bolnike (0,705 l/kg) nižji kot pri odraslih (0,801 l/kg).
Eurartesim should be administered over three consecutive days for a total of three doses taken at the same time each day. 
Zdravilo Eurartesim je treba dajati tri zaporedne dni ob isti uri, torej skupno tri odmerke.
You or your child should not take a second course of Eurartesim within 2 months of the first course. 
Vi ali vaš otrok ne smete prejeti drugega cikla zdravljenja z zdravilom Eurartesim v roku 2 mesecev od prvega zdravljenja.
In healthy male volunteers under fasting conditions, mean Cmax and AUCINF of artenimol ranged between 180-252 ng/ml and 516-684 ng/ml*h, respectively. 
Pri zdravih moških prostovoljcih je bil razpon povprečnega Cmax in AUCINF za artenimol med 180-252 ng/ml oz. 516-684 ng/ml*h v pogojih na tešče.
When co-administered to healthy women, Eurartesim exerted only a minimum effect on an estrogen/progestinic combination oral contraceptive treatment increasing the ethynilestradiol rate of absorption (expressed by geometric mean Cmax) of about 28% but not significantly changing the exposure to ethynilestradiol and levonorgestrel and not influencing contraception activity as demonstrated by the similar plasma concentrations of follicle stimulating hormone (FSH), luteinizing hormone (LH) and progesterone observed after oral contraceptive treatment with or without concomitant Eurartesim administration. 
Ko so sočasno dajali zdravilo Eurartesim zdravim ženskam, je le minimalno vplivalo na kombinirano peroralno kontracepcijsko terapijo z estrogenom in progestinom, tako da je zvečalo hitrost absorpcije etinilestradiola (izraženo z geometrično sredino Cmax) za okrog 28 %, a ni značilno spremenilo izpostavljenosti etinilestradiolu in levonorgestrelu in ni vplivalo na kontracepcijsko aktivnost, kot so pokazale podobne plazemske koncentracije folikle stimulirajočega hormona (FSH), luteinizirajočega hormona (LH) in progesterona, ki so jih ugotavljali po peroralni kontracepcijski terapiji s sočasnim dajanjem zdravila Eurartesim ali brez njega.
Piperaquine is also a substrate of CYP3A4. 
Piperakin je tudi substrat CYP3A4.